NovaSeq

The bearish case for Illumina, Inc. (NASDAQ: ILMN) has come to an end for four key reasons, according to Morgan Stanley. The Analyst Analyst Steve Beuchaw upgraded Illumina from Underweight to Equal-weight with a price target lifted from $210 to $320. The Thesis Illumina stands to benefit from...

Analysts at Baird turned bullish on Illumina, Inc. (NASDAQ: ILMN) in reaction to the company's third-quarter earnings report in which revenue grew at its fastest pace since the fourth quarter of 2015. Analyst Catherine Ramsey Schulte upgraded Illumina's stock from Neutral to Outperform with...

Shares of Illumina, Inc. (NASDAQ: ILMN) hit a new 52-week high of $198.47 Wednesday and ended the day higher by nearly 15 percent after the company reported top- and bottom-line beats in its second-quarter earnings report. However, the results weren't good enough for analysts at Barclays who are...

On Monday, Illumina, Inc. (NASDAQ: ILMN) announced preliminary Q4 results, while issuing the 2017 guidance and announcing the launch of its new sequencing platform, NovaSeq. Baird’s Catherine W. Ramsey maintains a Neutral rating on the company, while raising the price target from $147 to $153...